Cash, cash equivalents and short-term investments totaled $111.8M on December 31, 2018. CEO Krish Krishnan said, "Our top four priorities in 2019 are to commence the pivotal study of KB103 following completion of the Phase 1/2 GEM-1 study, initiate a Phase 1/2 clinical study of our second rare disease therapy, KB105, file an IND on an additional pipeline product, yet to be disclosed and begin work on our second, larger cGMP facility in Pittsburgh, to fully serve the production needs of our pipeline products."
https://thefly.com/landingPageNews.php?id=2877759
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.